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Post-Objective: BRCA1, a tumor suppressor gene implicated in breast and ovarian cancers, exerts multiple effects on
DNA repair and affords resistance against cellular stress responses. We hypothesized that BRCA1 limits endo-
thelial cell apoptosis and dysfunction, and via this mechanism attenuates atherosclerosis.
Methods: Loss and gain of function were achieved in cultured endothelial cells by silencing and overexpressing
BRCA1, respectively. In vivo loss and gain of function were performed by generating endothelial cell-specific
knockout (EC-BRCA1/) mice and administering a BRCA1 adenovirus. Well-established cell and animal
models of angiogenesis and atherosclerosis were used.
Results: BRCA1 is basally expressed in endothelial cells. BRCA1 overexpression protected and BRCA1 silenc-
ing exaggerated inflammation- and doxorubicin-induced endothelial cell apoptosis. Key indices of endothelial
function were modulated in a manner consistent with an effect of BRCA1 to limit endothelial cell apoptosis and
improve endothelial function. BRCA1 overexpression strongly attenuated the production of reactive oxygen
species and upregulated endothelial nitric oxide synthase, phosphorylated endothelial nitric oxide synthase,
phosphorylated Akt, and vascular endothelial growth factor-a expression. BRCA1 overexpression also improved
capillary density and promoted blood flow restoration in mice subjected to hind-limb ischemia. BRCA1-
overexpressing ApoE/ mice fed a Western diet developed significantly less aortic plaque lesions, exhibited
reduced macrophage infiltration, and generated less reactive oxygen species. Lung sections and aortic segments
from EC-BRCA1/ mice demonstrated greater inflammation-associated apoptosis and impaired endothelial
function, respectively. BRCA1 expression was attenuated in the plaque region of human atherosclerotic carotid
artery samples compared with the adjacent plaque-free area.
Conclusions: These data collectively highlight a previously unrecognized role of BRCA1 as a gatekeeper of
inflammation-induced endothelial cell function and a target to limit atherosclerosis. Translational studies eval-
uating endothelial function and atherosclerosis in individuals with BRCA1 mutations are suggested. (J Thorac
Cardiovasc Surg 2013;146:949-60)Supplemental material is available online.
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Abbreviations and Acronyms
ad ¼ adenovirus
CMV ¼ cytomegalovirus
Dox ¼ doxorubicin
EC ¼ endothelial cell
ENOS ¼ endothelial nitric oxide synthase
FITC ¼ fluorescein isothiocyanate
GAPDH ¼ glyceraldehyde 3-phosphate
dehydrogenase
GFP ¼ green fluorescent protein
HUVEC ¼ human umbilical vein endothelial cell
ICAM-1 ¼ intercellular adhesion molecule 1
MOI ¼ multiplicity of infection
oxLDL ¼ oxidized low-density lipoprotein
PCR ¼ polymerase chain reaction
PFU ¼ plaque-forming unit
ROS ¼ reactive oxygen species
siRNA ¼ small interfering RNA
SNP ¼ single nucleotide polymorphism
TNFa ¼ tumor necrosis factor-alpha
VCAM-1 ¼ vascular cell adhesion molecule 1
VEGF ¼ vascular endothelial growth factor
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Stranscriptional regulation, ubiquitination, and cell-cycle
control.2
DNA damage not only is important in cancer syndromes
but also represents a common pathophysiologic basis for di-
verse diseases characterized by increased cellular and oxi-
dative stress.3,4 Atherosclerosis, a leading cause of death
worldwide, is a chronic inflammatory condition, and
endothelial dysfunction plays an early and permissive role
in the development and progression of the disease.5 A com-
mon mechanism through which cardiovascular risk factors
lead to endothelial dysfunction is via increased generation
of reactive oxygen species (ROS), thus elevating oxidative
stress that in turn promotes DNA damage and endothelial
cell (EC) apoptosis.4
We recently demonstrated in mice a cardioprotective and
anti-inflammatory role for BRCA1.6,7 We have also
reported on the cardioprotective nature of BRCA2
(BReast CAncer susceptibility gene 2).8 Because BRCA1
plays an integral role in promoting DNA repair, we hypoth-
esized that BRCA1 also may be involved in regulating EC
survival and function, and thus may retard the progression
of atherosclerosis. We report for the first time that
BRCA1 limits EC apoptosis, restores endothelial function,
and attenuates atherosclerotic lesion development, thereby
highlighting a novel role for BRCA1 as a regulator of vas-
cular health. In addition to identifying a potentially new tar-
get for vascular diseases, these data may point toward
a heightened susceptibility of BRCA1 mutation carriers
toward atherothrombotic vascular diseases.950 The Journal of Thoracic and Cardiovascular SurgMATERIALS AND METHODS
A detailed, expanded Materials and Methods section is available in the
Online Supplement.
Cell Culture, Adenoviral Gene Delivery, and BRCA1
Gene Silencing
Human umbilical vein endothelial cells (HUVECs) were cultured in
MCDB-131 complete medium and used at passages 3 to 5. We used a cus-
tom-designed BRCA1 adenovirus (ad-BRCA1) that contained the com-
plete coding sequence of human BRCA1 (accession no. NM_007294.2)
and was under the control of the cytomegalovirus (CMV) promoter. Where
appropriate, ad-null (ad-CMV-null) or ad-green fluorescent protein (GFP)
served as controls for ad-BRCA1. BRCA1 gene silencing was achieved
with the small interfering RNA (siRNA) against human BRCA1, whereas
a combination of 4 scrambled siRNAs served as the negative control.
Animal Studies
All animal-associated procedures were performed in accordance with
the guidelines of the Canadian Council on Animal Care and approved by
the St Michael’s Hospital Animal Care Committee.
Male BALB/c mice from Charles River Laboratories International, Inc
(Wilmington, Mass) were used for hind-limb ischemia studies.
ApoE/ mice were obtained from The Jackson Laboratory (Bar Har-
bor, Me) and divided into 3 study groups. The first and second groups
were fed the Western diet for 4 and 16 weeks, respectively, while concur-
rently administered ad-GFP, ad-null, or ad-BRCA1. These mice were
subsequently euthanized, and their aortas were isolated for immunohisto-
chemical staining. The third group was fed the Western diet for 2 weeks,
after which plasma samples were collected for lipid analyses.
EC-specific BRCA1 knockout mice were generated by crossing Tie2
Cretg/ mice (The Jackson Laboratory) with BRCA1fl/fl mice (MMHCC, Na-
tional Cancer Institute, Frederick, Md) to generate Tie2-Cretg/; BRCA1fl/þ
(EC-BRCA1þ/) mice. EC-BRCA1þ/ mice were crossed with BRCA1fl/þ
mice to generate Tie2-Cretg/ BRCA1fl/fl (EC-BRCA1/) mice, which dem-
onstrate inactivation of the BRCA1 gene specifically in ECs.
Human Carotid Artery Samples
Study protocols were reviewed and approved by the Research Ethics
Boards of St Michael’s Hospital and Hamilton Health Sciences. Participa-
tion was voluntary, and all study subjects provided informed consent. Ca-
rotid artery segments were collected en bloc at the time of endarterectomy
from the intima to the external elastic lamina. Two sections were taken
from below (‘‘normal’’) and at (plaque containing) the carotid bifurcation.
Apoptosis Assays
Apoptosis in HUVECs was induced with 20 ng/mL human recombinant
tumor necrosis factor-alpha (TNFa), 10 mg/mL oxidized low-density lipo-
protein (oxLDL), or 2 mmol/L doxorubicin (Dox). The extent of apoptosis
was measured via flow cytometry by enumerating HUVECs positive for an-
nexin V–fluorescein isothiocyanate (FITC) and propidium iodide. Total
HUVEC genomic DNA samples were electrophoresed on 1% agarose
gels and subsequently stained with ethidium bromide for assessment of
DNA fragmentation. Lipopolysaccharide-induced lung injury as deter-
mined by the terminal deoxynucleotidyl transferase assay was examined
in EC-BRCA1þ/ mice.
Western Blot Analyses, RNA Extraction, and Real-
Time Polymerase Chain Reaction
Protein lysates were processed for Western blot analysis. Blots
were probed for BRCA1, endothelial nitric oxide synthase (eNOS),
Ser1177-phospho-eNOS, Akt, Ser473-phospho-Akt, cleaved caspase-3, vas-
cular cell adhesion molecule 1 (VCAM)-1, intercellular adhesion moleculeery c October 2013
Singh et al Evolving Technology/Basic Science1 (ICAM-1), E-selectin, and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Total RNA was prepared for polymerase chain reaction
(PCR) or real-time PCR reactions. Transcript levels of BRCA1,
VCAM-1, ICAM-1, E-selectin, vascular endothelial growth factor
(VEGF)-a, and GAPDH were quantified.
Quantification of Reactive Oxygen Species and
Vascular Endothelial Growth Factor Levels
ROS and VEGFa levels were determined with the OxiSelect ROSAssay
Kit (Cell Biolabs, Inc, San Diego, Calif) and a VEGF ELISA Kit (Thermo
Scientific, Burlington, Ontario, Canada) respectively.
In Vitro Angiogenesis and Migration
The angiogenic and migratory properties of HUVECs were examined
with the In Vitro Angiogenesis Assay Kit (Chemicon, Temecula, Calif)
and the CytoSelect 24-well Cell Migration Fluorometric Assay system
(Cell Biolabs, Inc), respectively.
Immunohistochemical and Immunofluorescent
Staining
Murine aortic root sections, human carotid artery sections, and en face
aorta samples were subjected to routine immunohistochemical staining
with BRCA1, Oil Red O, F4/80, or dihydroethidium. Sections of gastroc-
nemius muscles from the ischemic limbs of BALB/cmicewere stained with
rhodamine-conjugated isolectin-B4 and FITC-conjugated a-smooth mus-
cle actin.
Vascular Function
Endothelial function of the aortic segments from EC-BRCA1/ mice
was assessed via wire myography. Unilateral hind-limb ischemia was in-
duced in 8-week-old male BALB/c mice. Limb perfusion was monitored
by laser Doppler flow imaging for up to 28 days post-surgery.
Statistical Analysis
Unless otherwise stated, data are presented as mean  standard devia-
tion for the number of samples. The Student t test was applied when the
means of 2 groups were being compared. Differences between multiple
means were evaluated by analysis of variance, and when overall differences
were detected, individual means were compared post hoc with the Bonfer-
roni’s test.E
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BRCA1 Is Basally Expressed in Human Umbilical
Vein Endothelial Cells and Limits Human Umbilical
Vein Endothelial Cell Apoptosis After Inflammatory
and Genotoxic Stress
BRCA1 is basally expressed inHUVECs (FigureE1,A and
B). To evaluate the functional relevance of BRCA1 in HU-
VECs, we used gain- and loss-of-function strategies.
Optimal efficacy of adenoviral delivery was determined
with ad-GFP to be 20 multiplicity of infection (MOI). GFP
was detected 24 hours post-transfection in approximately
80% of HUVECs (Figure E1, C). Ad-BRCA1–mediated
BRCA1overexpressionwas confirmed byPCRand immuno-
blotting (Figure E1, A and B). The reader should note that
although all of the subsequent studies were performed in 3
groups of HUVECs—na€ıve (nontransfected) HUVECs, ad-
null–transfected HUVECs, and ad-BRCA1–transfectedThe Journal of Thoracic and CaHUVECs—only data from the ad-null– and ad-BRCA1–
treated groups are shown because findings from the na€ıve
and ad-null–transfected HUVECs were indistinguishable.
TNFa evoked significant apoptosis in ad-null–transfected
HUVECs but not in BRCA1-overexpressing HUVECs
(Figure 1, A). This observation was confirmed via immuno-
blots for cleaved caspase-3 and DNA fragmentation assays,
where BRCA1 overexpression dampened TNFa-associated
increases in cleaved caspase-3 protein levels (Figure 1, B)
and DNA fragmentation (Figure 1, C). That oxLDL not
only elevated the percentage of apoptotic HUVECs
(Figure 1, D) but also enhanced the levels of cleaved
caspase-3 (Figure 1, E) was not unexpected because EC
apoptosis induced by oxLDL is integral to the atherogenic
pathway. Of more interest was the observation that oxLDL-
triggered apoptosis also was significantly reduced in
BRCA1-overexpressing HUVECs (Figure 1,D and E). Gen-
otoxic stress caused by chemotherapeutic drugs, such asDox,
has been shown to activate apoptosis in ECs. We report
marked apoptosis in Dox-treated ad-null–transfected
HUVECs, an effect that was significantly reduced in ad-
BRCA1–transfected HUVECs (Figure 1, F and G). Loss of
function was performed with silenced-BRCA1 at an optimal
concentration of 10 nM (Figure 1, H). Apoptosis in TNFa-
treated BRCA1-silenced HUVEC cultures was significantly
greater compared with that in TNFa-treated control
HUVECs (Figure 1, I). These data suggest that BRCA1 pro-
tects HUVECs against apoptosis induced by inflammatory
and genotoxic stresses.
To gain critical insights into the role of BRCA1 in
endothelial regulation and to circumvent the embryonic
lethality associatedwith systemic BRCA1 loss,9 we generated
EC-BRCA1þ/ andEC-BRCA1/mice. Thesemicewere vi-
able, fertile, and born in the expected Mendelian ratios (data
not shown). Terminal deoxynucleotidyl transferase staining
revealed that, in comparison with the wild-type littermate
control group, lung sections from EC-BRCA1þ/ mice ex-
hibited more extensive lipopolysaccharide-associated
endothelial apoptosis (Figure 1, J).
BRCA1 Impairs Tumor Necrosis Factor-a–Induced
Reactive Oxygen Species Generation in Human
Umbilical Vein Endothelial Cells
BRCA1 reduces the generation of ROS,10,11 a critical
mediator of EC apoptosis elicited by TNFa,12 oxLDL,13
and Dox.14 We observed significantly lower levels of ROS
in ad-BRCA1–transfected HUVECs compared with ad-
null–treated HUVECs after TNFa stimulation (Figure 1,
K). Furthermore, we detected significantly higher levels of
ROS in TNFa-treated BRCA1-silenced HUVECs relative
to HUVECs that had been treated with the control siRNA
(Figure 1, L). These data demonstrate the importance of
BRCA1 in controlling ROS generation in HUVECs and ar-
guably HUVEC apoptosis.rdiovascular Surgery c Volume 146, Number 4 951
FIGURE 1. BRCA1 limits HUVEC apoptosis and ROS generation after inflammatory and genotoxic stress. A-C, After transfection with ad-null or
ad-BRCA1, HUVECs were incubated with 20 ng/mL TNFa or its diluent. A, Representative flow cytometry dot plots are shown on the left with the per-
centage of total apoptotic cells (quadrants S2þ S4) depicted quantitatively on the right. n¼ 3 in triplicate. *P<.01 versus ad-null group. yP<.01 versus ad-
null þ TNFa group. B, Representative immunoblots for cleaved caspase-3 and GAPDH. n ¼ 3 in triplicate. C, Total genomic DNA underwent agarose gel
electrophoresis for visualization of DNA fragmentation. The marker was from a nonadjacent lane on the same gel. D and E, After transfection, HUVECs
were treated with 10 mg/mL oxLDL or its diluent. D, Apoptosis was quantified as described in A. n¼ 3 in triplicate. *P<.01 versus ad-null group. yP<.01
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TNFa significantly impaired the capacity of HUVECs to
form capillary-like tubular structures, an effect that was not
evident in BRCA1-overexpressing HUVECs (Figure 2, A).
The marked attenuation of HUVEC migratory capacity by
TNFa was restored in BRCA1-overexpressing HUVECs
(Figure 2, B). VCAM-1, ICAM-1, and E-selectin have fun-
damental roles in maintaining endothelial function, and dis-
ruptions in their normal expression or function can
culminate in endothelial dysfunction. BRCA1 overexpres-
sion in HUVECs decreases VCAM-1 expression.10 In our
hands, transcript and protein levels of VCAM-1, ICAM-1,
and E-selectin were significantly upregulated by TNFa in
ad-null–treated HUVECs; these increases were appreciably
attenuated in BRCA1-overexpressing HUVECs (Figure 2,
C-E). These findings suggest a pivotal role for BRCA1 in
limiting inflammation-induced HUVEC activation and in
restoring the angiogenic capacity of HUVECs. Aortic rings
from EC-BRCA1/micewere significantly less responsive
to acetylcholine (Figure 2, F), suggestive of impaired
endothelial function (Emax for rings from EC-BRCA1
/
mice ¼ 58.23%  8.00%; Emax for rings from wild-type
mice ¼ 81.38%  6.70%) providing cogent ex vivo evi-
dence that BRCA1 is essential to endothelial homeostasis.
Smooth muscle function was unaffected by loss of the
BRCA1 gene as evidenced by the similar phenylephrine-
and sodium nitroprusside–induced responses recorded in
aortic rings from EC-BRCA1/ mice and their littermate
controls (data not shown).BRCA1 Promotes Endothelial Nitric Oxide Synthase,
Phosphorylated Endothelial Nitric Oxide Synthase,
Phosphorylated Akt, and Vascular Endothelial
Growth Factor-a Expression
ECs constitutively express eNOS, a critical regulator of
endothelial function that has been reported to be downregu-
lated by TNFa. We observed that TNFa markedly reduced
eNOS levels in ad-null–transfected HUVECs and thatversus ad-nullþ oxLDL group. E, Representative immunoblots for cleaved casp
were incubated with 2 mmol/L Dox or its diluent. F, Apoptosis was quantified as
versus ad-nullþDox group. G, Representative immunoblots for cleaved caspase
immunoblots derived from the total protein lysates of HUVECs transfected with
in triplicate. Solid lines through immunoblots demarcate nonadjacent lanes fro
siRNA, HUVECswere incubated with 20 ng/mLTNFa before the apoptotic cells
yP<.01 versus control siRNA þ TNFa group. J, Representative micrographs a
(arrows) in lung sections from lipopolysaccharide-treated EC-BRCA1þ/ and w
fection, HUVECs were incubated with 20 ng/mLTNFa or its diluent before RO
fluorescence. n ¼ 12. *P<.05 versus ad-null group. yP<.05 versus ad-null þ
control (scrambled) siRNA or siBRCA1 before incubation with TNFa. n ¼ 1
siBRCA1 þ TNFa group. BRCA1, BReast CAncer susceptibility gene 1; ad
3-phosphate dehydrogenase; TNFa, tumor necrosis factor-alpha; EC, endoth
HUVEC, human umbilical vein endothelial cell; mRNA, messenger RNA; oxLD
The Journal of Thoracic and CaeNOS levels were significantly upregulated in BRCA1-
overexpressing TNFa-treated HUVECs (Figure 3, A).
eNOS is a dynamic enzyme that is regulated in part by
Akt-dependent phosphorylation at the Ser1177 residue.15
TNFa-stimulated BRCA1-overexpressing HUVECs ex-
hibited increased eNOS-phosphorylation at the Ser1177
residue (Figure 3, A) and significantly greater Akt phos-
phorylation (Figure 3, B). BRCA1 overexpression enhances
VEGFa expression,16 and BRCA1 mutations in humans are
associated with significantly reduced serum VEGFa
levels.17 We report an approximately 15-fold upregulation
of VEGFa in BRCA1-overexpressing, TNFa-treated HU-
VECs relative to that in ad-null–transfected, TNFa-treated
HUVECs (Figure 3, C). VEGFa secretion in ad-BRCA1–
transfected, TNFa-treated HUVECs was significantly
higher than that in the corresponding ad-null–treated group
(Figure 3, D). These findings indicate that BRCA1 stimu-
lates eNOS expression at least in part via upregulation of
VEGFa and triggers eNOS activation through Akt
phosphorylation.BRCA1 Gene Therapy Improves Blood Flow
Recovery in Ischemic Hind Limbs
To evaluate the potential translational implications of
improved endothelial function in vivo, we examined the
extent of neovascularization that occurred after induction
of hind-limb ischemia in BALB/c mice. BRCA1 overex-
pression was confirmed through immunoblotting of tissue
lysates isolated from adductor muscles 8 days post-surgery
(Figure 4, A). As early as 8 days post-surgery, the ischemic
limbs of ad-BRCA1–treated mice demonstrated signifi-
cantly greater perfusion than those of mice that had
been administered ad-null (Figure 4, B and C). Perfusion
in the ischemic limb was consistently and significantly
greater in ad-BRCA1–treated mice (Figure 4, B and C).
Enhanced blood flow recovery in mice treated with ad-
BRCA1 versus ad-null was associated with higher capil-
lary densities at 28 days post-ischemia inductionase-3 and GAPDH. n¼ 3 in triplicate. F and G, After transfection, HUVECs
described in A. n ¼ 3 in triplicate. *P<.01 versus ad-null group. yP<.01
-3 and GAPDH. n¼ 3 in triplicate. H, Representative BRCA1 and GAPDH
the control (scrambled) siRNA or siBRCA1 before exposure to TNFa. n¼ 3
m the same Western blot. I, After treatment with siBRCA1 or the control
were enumerated. n¼ 3 in triplicate. *P<.01 versus control siRNA group.
nd quantification of terminal deoxynucleotidyl transferase–positive nuclei
ild-type littermate controls. n ¼ 3. *P<.05 versus control. K, After trans-
S levels were determined by measuring 2’, 7’-dichlorodihydrofluorescein
TNFa group. L, ROS production was measured in HUVECs treated with
2. *P< .05 versus scrambled siRNA group. yP< .05 versus scrambled
, adenovirus; ad-BRCA1, BRCA1 adenovirus; GAPDH, glyceraldehyde
elial cell; ROS, reactive oxygen species; siRNA, small interfering RNA;
L, oxidized low-density lipoprotein.
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FIGURE 2. BRCA1 restores key indices of endothelial function after TNFa treatment. A, After transfection with ad-null or ad-BRCA1, HUVECs
were transferred to a Matrigel-coated plate (BD Biosciences, San Jose, Calif) and treated with TNFa or its diluent. Representative micrographs showing
capillary-like tube formation in HUVECs 5 hours after treatment with TNFa. Tubular structures in 4 fields per group were semiquantitatively analyzed.
n ¼ 4 to 5 in triplicate. *P<.01 versus ad-null group. yP<.01 versus ad-null þ TNFa group. B, After transfection, HUVECs were treated with TNFa
or its diluent before the extent of cell migration was evaluated. n ¼ 4. *P<.01 versus ad-null group. yP<.01 versus ad-null þ TNFa group. C-E, Total
RNA and protein were extracted from ad-null and ad-BRCA1–transfected HUVECs that were subsequently treated with TNFa or its diluent. VCAM-1
(C), ICAM-1 (D), and E-selectin (E) transcript and protein levels after TNFa treatment. n ¼ 3. *P< .01 versus ad-null group. yP< .01 versus
ad-null þ TNFa group. F, Phenylephrine-contracted (106 mol/L) thoracic aorta segments from wild-type and EC-BRCA1/ mice were challenged
with 106 mol/L acetylcholine to assess endothelial function. n ¼ 4 to 5. *P<.05 versus wild-type control. BRCA1, BReast CAncer susceptibility gene
1; ad, adenovirus; ad-BRCA1, BRCA1 adenovirus; EC, endothelial cell; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TNFa, tumor necrosis
factor-alpha; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; WT, wild type; HUVEC, human umbilical vein
endothelial cell; mRNA, messenger RNA.
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role for BRCA1 in vivo.
BRCA1 Limits Atherosclerotic Lesion Formation
We confirmed successful delivery of ad-GFP by
imaging the extent of GFP fluorescence in the aortic roots
of ApoE/mice 4 weeks after initiation of the diet and ad-
enoviral treatment regimen (Figure E2, A). Immunohisto-
chemical staining of aortic root sections and immunoblots
performed with whole aorta lysates also revealed higher
levels of BRCA1 in ad-BRCA1–treated ApoE/ mice rel-
ative to that in ApoE/ mice administered ad-null
(Figure E2, B and C). Because the adenoviral vector used
in the current study contained the CMV promoter, the
expression of BRCA1 as a result of treatment with the954 The Journal of Thoracic and Cardiovascular Surgad-BRCA1 was not specific to the endothelium and was
also detected in cells other than aortic ECs (Figure E2, B).
Accordingly, we cannot exclude the involvement of cell
types other than ECs in the antiatherosclerotic effects de-
scribed in the subsequent figures.
Oil Red O staining suggest that mice treated with ad-
BRCA1 developed significantly less plaque compared
with those that had received ad-null (Figure 5, A). Immuno-
histochemical staining demonstrated less macrophage infil-
tration into the aortic roots, which is indicative of less
inflammation in ad-BRCA1–treated mice, compared with
ad-null–treated mice, maintained on the Western diet for
4 weeks (Figure 5, B). The less-extensive plaque deposition
and less severe inflammatory response that were associated
with ad-BRCA1 treatment occurred in parallel withery c October 2013
FIGURE 3. BRCA1 enhances eNOS, phosphorylated eNOS, phosphorylated Akt, and VEGFa expression. After transfection with ad-null or ad-BRCA1,
HUVECs were incubated with 20 ng/mLTNFa or its diluent. Representative immunoblots and semiquantitative data for (A) eNOS, phosphorylated eNOS,
and GAPDH, and (B) Akt, phosphorylated Akt, and GAPDH. C, Real-time PCR analysis of VEGFa transcript levels. D, VEGFa levels as determined
by enzyme-linked immunosorbent assay. n ¼ 12. *P<.01 versus ad-null group. yP<.01 versus ad-null þ TNFa group. BRCA1, BReast CAncer suscep-
tibility gene 1; ad, Adenovirus; ad-BRCA1, BRCA1 adenovirus; eNOS, endothelial nitric oxide synthase; p-eNOS, phosphorylated endothelial nitric
oxide synthase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TNFa, tumor necrosis factor-alpha; VEGF, vascular endothelial growth factor;
mRNA, messenger RNA.
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ad-BRCA1–treated ApoE/ mice (vs ad-null–treated
ApoE/ mice) was continuously and significantly lower
up to week 16 of the diet-adenoviral treatment (Figure 5,
D). The liver is often the main target for injected ad vectors.
Considering the role of the liver in the regulation of lipidThe Journal of Thoracic and Cametabolism and the implications of dysfunctional lipid biol-
ogy in the development and progression of atherosclerosis,
we collected plasma for lipid measurements from ApoE/
mice that had been on the Western diet for 2 weeks. Lipid
profiles of these mice were unaffected by the diet-
adenoviral treatment strategy (Table E1).rdiovascular Surgery c Volume 146, Number 4 955
FIGURE 4. BRCA1 improves recovery of ischemic hind limb. A, Representative immunoblot showing endogenous expression and BRCA1 overexpression
in murine adductor muscles 8 days post-surgery. n ¼ 2/group. B, Temporal changes in hind-limb perfusion. Data were calculated as the recovery of blood
flow to the ischemic foot normalized to the contralateral nonischemic foot. n ¼ 6 to 8. *P<.05 versus ad-null–treated group. C, Laser Doppler perfusion
images of adenoviral-treated ischemic and nonischemic contralateral hind-limbs at day 0 and day 8 post-surgery. D, Gastrocnemius muscles were harvested
28 days post-surgery for histologic processing. Micrographs depict capillary density in sections of gastrocnemius muscle as discerned by rhodamine-
conjugated isolectin-B4–positive areas (red, arrowheads). Arterioles were discriminated with FITC-conjugated smooth muscle a-actin (green, arrows).
n ¼ 6-8. *P<.05 versus ad-null–treated group. BRCA1, BReast CAncer susceptibility gene 1; ad-BRCA1, BRCA1 adenovirus; ad, adenovirus; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; FITC, fluroescein isothiocyanate.
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Artery Plaques
To gather insight into the potential involvement of
BRCA1 in the atherogenic process in humans, we measured
BRCA1 expression and levels in human carotid artery sam-
ples harvested from the point of bifurcation and the adjacent
control plaque-free area below the bifurcation (Figure 5, E).
Atherosclerosis in carotid arteries tends to occur stereotyp-
ically in the carotid bulb at or above the bifurcation,
whereas the region proximal to the bifurcation appears to
be grossly uninvolved in this pathology.18 BRCA1 mRNA
and protein levels in plaque-containing segments were sig-
nificantly lower compared with those in the control956 The Journal of Thoracic and Cardiovascular Surgsegments (Figure 5, F and G). Immunohistochemistry con-
firmed that segments obtained from the atherosclerotic
plaque region had less BRCA1-positive areas than those
from the control regions below the bifurcation point
(Figure 5, H).
DISCUSSION
Atherosclerosis, a leading cause of death and disability
worldwide, is a chronic inflammatory condition with EC ap-
optosis and endothelial dysfunction playing early and per-
missive roles in the development, progression, and
clinical course of the disease.5 The strategic location
of the endothelium allows it to ‘‘sense’’ changes inery c October 2013
FIGURE 5. BRCA1 limits atherosclerosis lesion formation in vivo, and BRCA1 expression is reduced in human carotid artery plaques.ApoE/micewere
treated with ad-GFP, ad-null, or ad-BRCA1 every 2 weeks while being maintained on the Western diet. A, Representative micrograph and quantification of
Oil Red O–defined atherosclerotic lesions (red orange) in the aortic roots of ad-null or ad-BRCA1–injected ApoE/mice fed the Western diet for 4 weeks.
n ¼ 9/group. *P<.01 versus ad-null–treated group. B, Representative micrograph and quantification of macrophage sequestration, as defined by F4/80
staining (brown), in the aortic roots of ad-null or ad-BRCA1–injected ApoE/ mice fed the Western diet for 4 weeks. n ¼ 9/group. *P<.01 versus ad-
null–treated group. C, Representative micrograph and quantification of dihydroethidium staining (red, ROS production) in aortic root sections from
ApoE/ mice maintained on the Western diet for 4 weeks. n ¼ 9/group. *P<.01 versus ad-null–treated group. Data are presented as the mean of 4 to
5 fields as positive stained percent of total root area. D, Representative samples and quantification of Oil Red O–defined atherosclerotic lesions in en
face preparations of descending aortas from ApoE/mice maintained on the Western diet for 16 weeks and administered ad-null or ad-BRCA1 every sec-
ond week. n ¼ 9/group. *P<.01 versus ad-null–treated group. E, Diagram outlines the control and plaque containing regions. Total RNA and protein were
extracted from carotid artery samples for determination of BRCA1 levels via (F) real-time PCR analysis, and (G) immunoblotting. n¼ 3 to 4. *P<.05 versus
control. H, Representative micrographs showing BRCA1 positivity (brown) in carotid artery sections obtained from control and plaque-containing regions.
n¼ 3 to 4. BRCA1, BReast CAncer susceptibility gene 1; ad-BRCA1, BRCA1 adenovirus; ad, adenovirus;DHE, dihydroethidium;GAPDH, glyceraldehyde
3-phosphate dehydrogenase; PCR, polymerase chain reaction; ROS, reactive oxygen species; GFP, green flourescent protein.
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spond’’ by releasing a number of bioactive factors. EC ap-
optosis and dysfunction disrupt the balance between these
bioactive factors, thereby predisposing the vessel wall to
vascular inflammation, leukocyte adherence, platelet acti-
vation, pro-oxidation, thrombosis, and impaired coagula-
tion leading to atherosclerosis.3,4
DNA damage–induced apoptosis is purported to play an
important role in the development of endothelialThe Journal of Thoracic and Cadysfunction and atherosclerosis. This line of thought is
strengthened by recent data showing that deficiency in the
ataxia telangiectasia mutated kinase, a critical regulator of
DNA damage repair, worsens features of metabolic syn-
drome and accelerates atherosclerosis in ApoE/ mice.19
It has also been reported that atherosclerosis is decreased
in ApoE/ mice treated with an ataxia telangiectasia mu-
tated kinase activator that is suggestive of a causal role
for DNA damage-response pathways in atherosclerosis.19rdiovascular Surgery c Volume 146, Number 4 957
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SAlthough the role of BRCA1 in DNA damage repair re-
sponses has been largely studied in cancer, this work sup-
ports the contention that BRCA1 is a critical modulator of
EC apoptosis, endothelial dysfunction, and atherosclerosis,
all of which are characterized by aberrant DNA damage and
cellular stress. We provide evidence that BRCA1 is ex-
pressed in HUVECs and that it is capable of protecting
HUVECs from undergoing apoptosis induced by various
stressors that include TNFa, oxLDL, and Dox. We also
demonstrate that BRCA1 silencing exaggerates TNFa-in-
duced HUVEC apoptosis.
Both inflammation and genotoxic stress induce apoptosis
via ROS generation,12-14 and ROS-induced DNA damage
may play an important role in the development of cancer
and inflammatory diseases. Evidence to date suggests that
several proatherogenic stimuli trigger ROS production in
ECs and that the resultant oxidative stress plays a key role
in mediating the pathologic manifestations of EC apoptosis
and endothelial dysfunction that are associated with athero-
sclerosis. Because BRCA1 not only affords protection
against DNA damage but also reduces ROS generation,10,11
we measured ROS levels in HUVECs after TNFa treatment
and found that BRCA1 overexpression reduces and BRCA1
silencing enhances TNFa-induced ROS production,
thereby confirming that BRCA1 may protect ECs against
apoptosis by negatively regulating stress-induced ROS
generation.
In the milieu of cardiovascular risk factors that disturb
vascular homeostasis, the endothelium becomes dysfunc-
tional resulting in perturbed angiogenesis and enhanced ex-
pression of cellular adhesion molecules by the endothelium.
Our current data indicate that key indices of endothelial
function, such as the ability of ECs to form capillary-like
tubes, migrate, and express surface markers of endothelial
injury (VCAM-1, ICAM-1, and E-selectin), and the reduced
response of aortic rings from EC-BRCA1/mice to acetyl-
choline ex vivo, are modulated in a manner consistent with
an effect of BRCA1 to limit EC apoptosis and improve en-
dothelial function. Indeed, our results demonstrating signif-
icant upregulation of eNOS and VEGFa expression, as well
as elevatedAkt activation in BRCA1-overexpressing TNFa-
stimulated HUVECs, suggest that the restorative nature of
BRCA1 on endothelial function occurs at least in part
through enhanced eNOS expression via VEGFa upregula-
tion and eNOS activation by means of Akt phosphorylation,
both of which are recognized survival mechanisms in ECs.
There seems to be no consensus as yet on the associative
relationship between BRCA1 and VEGFa expression and
activity. Kawai and colleagues20 demonstrated that wild-
type BRCA1 inhibited VEGFa promoter activity and
secretion in breast cancer cells by modulating the estrogen
receptor in a dose-dependent manner and primarily in the
presence of estrogen. In contrast to the study by Kawai
and colleagues but in agreement with ours, Kang and958 The Journal of Thoracic and Cardiovascular Surgcolleagues16 found that elevation of BRCA1 levels in breast
cancer cells enhanced VEGF promoter activity after expo-
sure to conditions of hypoxia and increased VEGF mRNA
levels. The same authors showed that silencing of endoge-
nous BRCA1 resulted in decreased hypoxia-stimulated
VEGF promoter activity and secretion. In an article by
Welcsh and King,21 overexpression of wild-type BRCA1
in prostrate and breast cancer cell lines was associated
with an approximately 2.5-fold increase in VEGFa expres-
sion in the setting of oxidative stress.21 At the clinical level,
significantly lower levels of VEGFwere detected in patients
with mutation of the BRCA1 gene when compared with pa-
tients with breast cancer without this mutation.11 The bal-
ance of current data suggests that how BRCA1 modulates
VEGFa expression and activity may be particularly depen-
dent on the cell type, the presence of necessary cofactors,
and whether the cells being studied are primary cells or
a transformed cancer cell line.
By using a mouse model of neoangiogenesis after induc-
tion of hind-limb ischemia, we successfully translated our
in vitro data to the in vivo level. Treatment with ad-
BRCA1 not only improved capillary density but also
restored blood flow to the ischemic limb. BRCA1 gene ther-
apy also limited the formation of atherosclerotic lesions and
attenuated inflammation, macrophage infiltration, and ROS
generation but had no effect on lipid metabolism. These
data are critical because they represent an accepted transla-
tional end point of progressive endothelial dysfunction. Of
note, the benefits of BRCA1 on endothelial dysfunction and
ROS may be more applicable to the chronic experiments on
endothelial dysfunction and atherosclerosis, as opposed to
the setting of acute reperfusion injury, which shares many
of the contributory factors. We also provide preliminary
clinical confirmation in human atherosclerotic plaques
wherein reduced BRCA1 levels are observed relative to
plaque-free areas of the same vessel.
Our work collectively highlights a previously unrecog-
nized role of BRCA1 as a gatekeeper of EC survival and
function, and through this mechanism a novel target to im-
prove ischemic neovascularization and attenuate athero-
sclerosis. Our data may also provide clues regarding the
potential susceptibility of patients with mutations of the
BRCA1 gene to atherosclerotic vascular disease, in addition
to cancer. Reports have suggested unknown effects of
BRCA1 mutations on non-neoplastic deaths, particularly
at older ages.22 Individuals with BRCA1 mutations seem
to face a 2-fold increased risk of developing diabetes, a dis-
ease characterized by increased endothelial dysfunction, in-
flammation, and atherosclerosis.23 Single nucleotide
polymorphisms (SNPs) in the BRCA1-associated protein
have been linked to risk of myocardial infarction in Asian
populations.24 Zbuk and colleagues25 recently reported an
association between 2 BRCA2 SNPs and cardiovascular
disease in a multiethnic population,25 and Asselbergs andery c October 2013
Singh et al Evolving Technology/Basic Sciencecolleagues26 found a strong association between 2 other
BRCA2 SNPs and low-density lipoprotein and total choles-
terol levels in a large-scale, gene-centric meta-analysis.
Collectively, these studies support the contention for clini-
cal and population-based research.
Ad- or lentivirus-mediated tissue-specific (myocardial)
and systemic gene therapy have successfully been
demonstrated.7,27-29 Our data suggest that BRCA1 cell or
gene therapy approaches that target DNA damage repair
mechanisms may represent a novel approach to treat native
and vein graft atherosclerosis—diseases characterized by
endothelial dysfunction. This therapy may have additional
benefits in surgical patients who develop severe sepsis,
a disease also characterized by pronounced endothelial
injury. Indeed, we have recently demonstrated that BRCA1
gene delivery before induction of experimental sepsis
reduces systemic inflammatory response and multiple
organ failure and improves survival in mice.7 The benefits
of BRCA1 on cardiovascular protection seem to involve
both thevascular endothelium and themyocardium.Our pre-
vious work6 coupled with the current article suggests that
BRCA1-based gene therapy may have the potential to limit
both ischemic and genotoxic cardiac failure, while also lim-
iting the process of endothelial injury and atherogenicity.Study Limitations
This study has a few limitations that should be men-
tioned. Because the ad vectors that we used were under
the control of the CMV promoter, the results that we report
cannot be specifically associated with ECs. Accordingly,
we are unable to rule out any role that may be played by
other cell types as a result of the ensuing BRCA1 overex-
pression. Although our data from the human carotid sam-
ples suggest a potential association between reduced
BRCA1 expression and plaque formation, they are prelim-
inary and speculative, and do not provide any evidence of
causality.SCONCLUSIONS
Several lines of investigation arewarranted.Definitive stud-
ies evaluating plaque burden in EC-specific BRCA1 knockout
on the apolipoprotein-E background (EC-BRCA1/;
ApoE/ double knockout) mice should be performed.
Studies in larger animal models of coronary endothelial dys-
function (eg, the porcine model) also should be performed to
confirm these observations. Finally, genetic studies evaluating
whether SNPs in BRCA1/2 are linked to cardiovascular dis-
ease, such as those by Zbuk and colleagues25 and Asselbergs
and colleagues,26 should be performed.E
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Cell Culture, Adenoviral Gene Delivery, and BRCA1
Gene Silencing
HUVECs and MCDB-131 complete medium were obtained from Clo-
netics (VEC Technologies, Inc, Rensselaer, NY). Studies were performed
on cultured HUVECs at passages 3 to 5.
We used a custom-designed BRCA1 adenovirus (ad-BRCA1; Vector
BioLabs, Philadelphia, Pa) that contained the complete coding sequence
of human BRCA1 (accession no. NM_007294.2) and was under the control
of the CMV promoter. Ad-null (ad-CMV-null) or ad-GFP (both from Vec-
tor BioLabs), both also under the control of the CMV promoter, served as
controls for ad-BRCA1. The entire transfection process took 24 hours, after
which HUVECswere processed as required for various analyses. As shown
in Figure E1, optimal adenoviral transfection efficacy was achieved at 20
MOI.
Before study initiation, the siRNA against human BRCA1 (BRCA1
siRNA SMARTpool) or the negative control (consisting of 4 scrambled
siRNAs) were incubated with OptiMEM (Invitrogen, Burlington, Ontario,
Canada) and the siPORT NeoFX Transfection Agent (Ambion, Burling-
ton, Ontario, Canada) per the manufacturer’s instructions. HUVECs
were plated in 6-well plates at a density of 1.5 3 105/well for the
24-hour transfection process. Optimal siBRCA1 concentration was deter-
mined in preliminary studies to be 10 nM. After transfection, HUVECs
were washed in PBS and maintained for an additional 24 hours in
MCDB-131 complete medium before incubation with TNFa for 24 hours.
HUVECs were then processed for flow cytometry studies or protein ex-
pression analysis.Animal Studies
All of the procedures that were performed on animals were in accor-
dance with the guidelines of the Canadian Council on Animal Care and
were approved by the St Michael’s Hospital Animal Care Committee.
Male BALB/cmice were from Charles River Laboratories International,
Inc (Wilmington, Mass), and ApoE/ mice were from The Jackson Lab-
oratory (Bar Harbor, Me).
EC-specific BRCA1 knockout mice were generated by crossing Tie2
Cretg/ mice (The Jackson Laboratory), wherein the Tie2 promoter drives
Cre recombinase expression, with BRCA1fl/fl (where exon 11 of the
BRCA1 gene is flanked by 2 loxP sites) mice (MMHCC, National
Cancer Institute, Frederick, Md) to generate Tie2-Cretg/; BRCA1fl/þ
(EC-BRCA1þ/) mice. EC-BRCA1þ/ mice were crossed with BRCA1fl/þ
mice to generate Tie2-Cretg/; BRCA1fl/fl (EC-BRCA1/) mice, which
demonstrate inactivation of the BRCA1 gene specifically in ECs.Human Carotid Artery Samples
Study protocols were reviewed and approved by the Research Ethics
Boards of St Michael’s Hospital and Hamilton Health Sciences before
study commencement. Participation was voluntary, and all study subjects
provided informed consent. Carotid artery segments were collected en
bloc at the time of endarterectomy from the intima to the external elastic
lamina. Two sections were taken from below (‘‘normal’’) and at (plaque
containing) the carotid bifurcation. Onewas snap-frozen in liquid nitrogen,
and the other was fixed and embedded in Tissue-Tek optimum cutting tem-
perature (Sakura Finetek, Torrance, Calif).E
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Human recombinant TNFa (R&D, Burlington, Ontario, Canada),
oxLDL (Biomedical Technologies Inc, Stoughton,Mass), and Dox (Sigma,
Oakville, Ontario, Canada) were purchased. Optimal TNFa, oxLDL, and
Dox concentrations for inducing significant apoptosis after 24 hours of
treatment were determined in preliminary experiments to be 20 ng/mL,
10 mg/mL, and 2 mmol/L, respectively. Where appropriate, the controlThe Journal of Thoracic and Cardgroups were treated with the respective diluents: PBS for TNFa and
oxLDL, and water for Dox.
HUVECs, at 50% to 60% confluency, were transfected with ad-null
or ad-BRCA1. At the end of the transfection process, HUVECs were
treated with TNFa, Dox, or oxLDL for an additional 24 hours before
the extent of apoptosis was measured by enumerating HUVECs posi-
tive for Annexin V–FITC and propidium iodide (both from BD Biosci-
ences, Mississauga, Ontario, Canada) via flow cytometry. Fluoresceins
were excited at 488 nm, and emissions were detected at 512 nm and
543 nm on a Cytomics FC500 system (Beckman Coulter Inc, Carlsbad,
Calif). The dots in quadrants S2 and S4 represent late and early apo-
ptotic events, respectively. The percentage of total apoptotic cells
(S2 þ S4) is presented in the accompanying graphs as percent apopto-
tic cells.
HUVECs were cultured in 100-mm dishes and transfected with ad-null
or ad-BRCA1 on reaching 50% to 60% confluency. At the end of the trans-
fection protocol, HUVECs were treated with TNFa or its diluent for an ad-
ditional 24 hours before total genomic DNAwas extracted using standard
protocols and 20 mg of genomic DNA electrophoresed on 1% agarose gels
that were subsequently stained with ethidium bromide for assessment of
DNA fragmentation.
Lipopolysaccharide-induced lung injury as determined by the terminal
deoxynucleotidyl transferase assay was examined in EC-BRCA1þ/ mice.Western Blot Analyses
Protein lysates from HUVECs, mouse, and human tissues were ex-
tracted in RIPA buffer (Sigma) supplemented with a protease inhibitor
cocktail (Roche, Mississauga, Ontario, Canada). Protein concentrations
were determined with the Bradford Dye Binding Assay (Bio-Rad, Mis-
sissauga, Ontario, Canada), and 40- to 80-mg sample loads were resolved
on sodium dodecyl sulfate-polyacrylamide gels, electrotransferred onto
nitrocellulose membranes, and probed with antibodies against BRCA1
(1:200), eNOS (1:1000), Ser1177-phospho-eNOS (1:1000), Akt
(1:1000), Ser473-phospho-Akt (1:1000), cleaved caspase-3 (1:1000),
VCAM-1 (1:1000), ICAM-1 (1:1000), E-selectin (1:1000), or GAPDH
(1:2000). After incubation with the appropriate horseradish peroxi-
dase–conjugated secondary antibodies, immunocomplexes were visual-
ized by enhanced chemiluminescence (GE Healthcare, Mississauga,
Ontario, Canada), and band intensity was quantified by densitometry us-
ing ImageJ software. BRCA1 and secondary antibodies were from Santa
Cruz Biotechnology (Santa Cruz, Calif). The GAPDH antibody was
from Chemicon (Ontario, Canada). The eNOS antibody was from BD
Biosciences (Temecula, Calif). VCAM-1 and E-selectin antibodies
were from Abcam (Cambridge, Mass). All other antibodies were from
Cell Signaling Technology, Inc (Danvers, Mass).RNA Extraction and Real-Time Polymerase Chain
Reaction
Total RNAwere extracted with the RNeasy Plus Mini Kit (Qiagen, Tor-
onto, Ontario, Canada) and reverse-transcribed with the Quantitect Reverse
Transcription Kit (Qiagen) before undergoing PCR or real-time PCR on
the ABI 7900HT Fast Real-Time PCR System (Applied Biosystems,
Carlsbad, Calif). Transcripts were quantified using the following primer
pairs: 50-TCAAGGAACCTGTCTCCACA-30 and 50-CTTTCTTGTAGG
CTCCTTTTGG-30 for BRCA1, 50-TGGGAAAAACAGAAAAGAGG
TG-30 and 50-GTCTCCAATCTGAGCAGCAA-30 for VCAM-1, 50-TG
ATGGGCAGTCAACAGCTA-30 and 50-AGGGTAAGGTTCTTGCC
CAC-30 for ICAM-1, 50-AAGCCTTGAATCAGACGGAA-30 and 50-TC
CCTCTAGTTCCCCAGATG-30 for E-selectin, 50-CTACCTCCACCAT
GCCAAGT-30 and 50-AGCTGCGCTGATAGACATCC-30 for VEGFa,
and 50-CACCAGGGCTGCTTTTAACTCTGGTA-30 and 50-CCTTGA
CGGTGCCATGGAATTTGC-30 for GAPDH.iovascular Surgery c Volume 146, Number 4 960.e1
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Vascular Endothelial Growth Factor Levels
HUVECs underwent transfection or silencing before they were treated
for 12 hours with TNFa. ROS production was determined by the fluores-
cent intensity of 20, 70-dichlorodihydrofluorescein (ex/em: 480 nm/530
nm) using the OxiSelect ROS Assay Kit (Cell Biolabs, Inc, San Diego,
Calif). VEGFa levels in HUVECs that had been transfected with ad-null
or ad-BRCA1 before treatment with TNFa for 24 hours were quantified
with a Human VEGF ELISA Kit (Thermo Scientific, Burlington, Ontario,
Canada).
In Vitro Angiogenesis
The InVitroAngiogenesisAssayKit (Chemicon)was used to examine the
angiogenic properties of ad-null– and ad-BRCA1–transfected HUVECs that
had been incubated at 37C in the absence or presence of TNFa. HUVECs
were seeded onto ECMatrix Gel–coated 96-well plates (Millipore, Billerica,
Mass) at a density of 9 3 103/well. The extent of angiogenesis was deter-
mined with the aid of a phase-contrast microscope (Nikon, Tokyo, Japan)
5 hours post-plating. Each experiment was performed thrice in triplicates.
Migration Assay
Ad-null– and ad-BRCA1–transfected HUVECs were suspended in
serum-free MCDB-131 medium and plated at a density of 0.25 3 106/
well, in the absence or presence of TNFa, in the upper chambers of a Cyto-
Select 24-well Cell Migration Fluorometric Assay system (Cell Biolabs,
Inc). Ten percent fetal bovine serum complete MCDB-131 medium was
added to the lower chambers and acted as the chemoattractant. After incu-
bation for 12 hours at 37C, the fluorescence emitted by the cells that had
migrated to the lower chambers was quantified with the Thermo Scientific
Fluoroskan Ascent FL Luminometer (ex/em: 480 nm/520 nm). Each exper-
iment was performed thrice in triplicates.
Immunohistochemistry
Cryosections (5 mm) of OCT-embedded murine aortic root and human
carotid artery samples were subjected to immunohistochemical staining us-
ing standard methods and visualized with a DAB substrate (Vector Labora-
tories, Burlington, Ontario, Canada), and the degree of staining was
quantified with the NIH ImageJ analysis software.
Endothelial Function and Hind-Limb Ischemia
Endothelial function in aortic segments from EC-BRCA1/ mice was
studied via wire myography.
Unilateral hind-limb ischemiawas induced in 8-week-oldmale BALB/c
mice. The left femoral artery was ligated and excised distal to the origin of
the deep femoral artery and proximal to the popliteal artery. Either ad-
BRCA1 or ad-null (20 mL of 1010 PFU/mL, intramuscularly) was adminis-
tered on days 0 (immediately after surgery) and 14 at 5 different points in960.e2 The Journal of Thoracic and Cardiovascular Sthe ischemic adductor muscle. Perfusion in the ischemic limb and the con-
tralateral control limb was monitored by laser Doppler flow imaging before
and immediately after surgery, and on postoperative days 4, 8, 16, and 28.
On day 28, mice were euthanized, and the gastrocnemius muscles from the
ischemic limbs isolated, embedded, and frozen in OCT cryosections (5 mm)
were stained with rhodamine-conjugated isolectin-B4 to aid in the identi-
fication of capillaries and with FITC-conjugated a-smooth muscle actin
to discriminate arterioles. Capillary density, as defined by the number of
isolectin-B4–positive areas over 5 to 7 microscopic fields, was determined
using the NIH ImageJ software by an investigator blinded to the treatment
groups.
Atherosclerotic Lesion and In Situ Reactive Oxygen
Species Production
Eight-week-old male ApoE/ mice were fed the Western diet for 4
weeks and concurrently administered ad-GFP, ad-null, or ad-BRCA1
(20 m of 1010 PFU/m) via the tail vein on days 0 and 14 of the study pe-
riod. At the end of week 4, mice were euthanized and their aortic roots
were isolated and embedded in OCT for cryosectioning (5 mm). Sections
were stained with BRCA1, Oil Red O, F4/80, or dihydroethidium (Molec-
ular Probes, Burlington, Ontario, Canada) to determine the extent of
BRCA1 expression, areas of atherosclerotic lesions, macrophage infiltra-
tion, and ROS production, respectively. Atherosclerotic lesions were iden-
tified by manually tracing the entire Oil Red O–positive areas and
quantified with the NIH ImageJ analysis software. Macrophage infiltration
was determined by coupling the F4/80 antibody to a DAB substrate. To
measure ROS production, dihydroethidium (0.30 mmol/L) was applied
topically to each section. After 30 minutes of incubation at 37C, sections
were washed in PBS before they were overlaid with a coverslip. Fluores-
cent images of the sections were captured with a Nikon Eclipse E800 fluo-
rescent microscope (Nikon, Tokyo, Japan) and quantified with the NIH
ImageJ analysis software. A second group of ApoE/ mice were main-
tained on the Western diet for 16 weeks and concomitantly treated on
day 0 and every second week thereafter with ad-null or ad-BRCA1 (20
mL of 1010 PFU/mL). At the end of week 16, en face preparations of
the whole aortas were stained with Oil Red O, and the stained areas
were quantified with the NIH Image J analysis software. A third group
of ApoE/ mice were fed the Western diet for 2 weeks, after which
plasma samples were collected for evaluation of lipid levels through the
in-house hospital laboratory services.
Statistical Analysis
Unless otherwise stated, data are presented as mean  standard devia-
tion for the number of samples. The Student t test was applied when the
means of 2 groups were being compared. Differences between multiple
means were evaluated by analysis of variance, and when overall differences
were detected, individual means were compared post hoc with the Bonfer-
roni’s test.urgery c October 2013
FIGURE E1. BRCA1 overexpression in HUVECs and adenoviral transfection efficiency. A and B, Total RNA and protein were extracted from untrans-
fected HUVECs and HUVECs that had been transfected 24 hours previously with ad-null or ad-BRCA1 (both 20 MOI). A, Representative image of an
agarose gel showing the PCR products for BRCA1-specific and GAPDH primers with equal amounts of cDNA demonstrating basal expression of
BRCA1 in untreated and ad-null–transfected HUVECs, as well as BRCA1 overexpression in ad-BRCA1–transfected HUVECs. B, Representative immuno-
blot supporting the transcript data in A at the protein level. GAPDH was used as a loading control. n ¼ 3 to 4 in triplicate. C, Twenty-four hours post-
transfection with 20 MOI of ad-GFP, approximately 80% of the HUVECs were positive for GFP staining. n ¼ 3 to 4 in triplicate. BRCA1, BReast CAncer
susceptibility gene 1; ad, adenovirus; ad-BRCA1, BRCA1 adenovirus; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HUVEC, human umbilical
vein endothelial cell; PCR, polymerase chain reaction; MOI, multiplicity if infection; cDNA, complementary DNA; GFP, green flourescent protein.
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TABLE E1. Lipid profiles of ApoE/mice treated with ad-null or ad-
BRCA1 and maintained on the Western diet for 2 weeks
Lipid (mmol/L) ad-null (n ¼ 8) ad-BRCA1 (n ¼ 7)
Total cholesterol 18.1  3.31 16.6  1.7
High-density lipoprotein
cholesterol
0.64  0.16 0.72  0.21
LDL cholesterol 7.54  1.6 7.94  1.45
Very LDL cholesterol 7.61  1.57 7.17  0.81
Triglycerides 0.67  0.16 0.77  0.24
Data are presented as mean  standard deviation. BRCA1, BReast CAncer suscepti-
bility gene 1; LDL, low-density lipoprotein; ad, adenovirus.
FIGURE E2. Efficiency of adenoviral therapy and BRCA1 overexpres-
sion in ApoE/ mice. ApoE/ mice were treated with ad-GFP, ad-null,
or ad-BRCA1 every 2 weeks while being fed the Western diet. A, Repre-
sentative micrograph showing GFP fluorescence in the aortic root of an
ApoE/mouse treated with ad-GFP and fed the Western diet for 4 weeks.
B, Representative micrograph showing BRCA1 positivity (brown) in the
aortic root of an ApoE/mouse treated with ad-BRCA1 and fed the West-
ern diet for 4 weeks. C, Representative immunoblot with whole aortic ly-
sates confirming endogenous expression of BRCA1 in ad-null–treated
mice and BRCA1 overexpression in ad-BRCA1–injected mice. n ¼ 3/
group. BRCA1, BReast CAncer susceptibility gene 1; ad-GFP, adenovirus
green fluorescent protein; ad-BRCA1, BRCA1 adenovirus; GAPDH, glyc-
eraldehyde 3-phosphate dehydrogenase.
960.e4 The Journal of Thoracic and Cardiovascular Surgery c October 2013
Evolving Technology/Basic Science Singh et al
E
T
/B
S
